Skip to main content
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. — Investor Relations & Filings

Ticker · SCNI ISIN · US09073Q3039 US Manufacturing
Filings indexed 467 across all filing types
Latest filing 2026-05-12 Foreign Filer Report
Country US United States of America
Listing US SCNI

About Scinai Immunotherapeutics Ltd.

https://www.scinai.com/

Scinai Immunotherapeutics Ltd. is a clinical-stage biopharmaceutical company operating through two complementary business units. Its internal research and development division focuses on developing innovative biological products for inflammation and immunology (I&I), targeting autoimmune and infectious diseases. The core of its therapeutic pipeline is a platform of Alpaca-derived nanosized antibodies (NanoAbs or VHH-antibodies), developed for conditions such as psoriasis and asthma. The company's second unit, Scinai Bioservices, is a Contract Development and Manufacturing Organization (CDMO). It provides end-to-end services to biotech companies, supporting drug development from early research and process development through to cGMP-compliant manufacturing for clinical trials up to Phase 3.

Recent filings

Filing Released Lang Actions
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Foreign Filer Report
2026-05-12 English
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Foreign Filer Report
2026-05-08 English
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Foreign Filer Report
2026-04-27 English
20-F - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Annual Report FY 2025
2026-04-01 English
3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)
Director's Dealing
2026-03-26 English
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Foreign Filer Report
2026-03-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.